Early Warning System

EBRD-55003

Polpharma Generics & Biotech

Early Warning System
Polpharma Generics & Biotech

EBRD-55003

Quick Facts

Countries	Poland
Financial Institutions	European Bank for Reconstruction and Development (EBRD)
Status	Approved
Bank Risk Rating	B
Voting Date	2024-02-21
Borrower	Zaklady Farmaceutyczne Polpharma S.A.; Windstorm Trading and Investments Limited
Sectors	Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	$ 159.76 million
Project Cost (USD)	$ 788.92 million

Project Description

According to the Bank’s website, the project consists of long-term financing to Zaklady Farmaceutyczne Polpharma S.A. ("Polpharma") and Windstorm Trading and Investments Limited (together referred to as the "Group", the "Client") as part of a larger syndicate to support an investment program involving business expansion and R&D activities of both generics and biologics divisions of the Group, as well as for general corporate purposes and refinancing.

The project will strengthen the Group's position in Poland, Central and Eastern Europe and other export markets and increase its global presence through value added products. The investments into the new biological products will allow the Group to establish region-leading competencies in advanced pharmaceutical production and facilitate the global commercialization of its pipeline of biological therapeutics in partnership with the world's largest pharmaceutical companies, thus entering currently unavailable market segments.

Early Warning System Project Analysis

Categorised B (ESP 2019). Environmental and social risks associated with capex investment at existing operational sites and R&D expenditure in the highly regulated pharma industry are site specific and can be readily mitigated.

Investment Description

- European Bank for Reconstruction and Development (EBRD)

Private Actors Description

Polpharma is among the 20 largest generics companies in the world. The company has 7 production plants in Poland, Russia and Kazakhstan, and 7 centers of research and development. Polpharma Group's portfolio includes about 600 products, and another 200 are under development. Polpharma SA specializes in cardiology, gastroenterology and neurology. A significant part of the product portfolio are the medications available over the counter (OTC). The company offer also includes dietary supplements, medical devices, cosmetics and herbal medicines.

Windstorm is a privately owned *investment* and holding company located in the ancient town of Larnaca on the southern coast of Cyprus.

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	WINDSTORM TRADING AND INVESTMENTS LIMITED	Client	-
-	-	-	-	ZAKLADY FARMACEUTYCZNE POLPHARMA SA	Client	-

Contact Information

COMPANY CONTACT INFORMATION

Magdalena Rzeszotalska
magdalena.rzeszotalska@polpharma.com
00 48 607 696 473
www.polpharma.pl

ACCESS TO INFORMATION

You can request information by emailing: accessinfo@ebrd.com or by using this electronic form: https://www.ebrd.com/eform/information-request

ACCOUNTABILITY MECHANISM OF EBRD

The Project Complaint Mechanism (PCM) is the independent complaint mechanism and fact-finding body for people who have been or are likely to be adversely affected by an European Bank for Reconstruction and Development (EBRD)-financed project. If you submit a complaint to the PCM, it may assess compliance with EBRD's own policies and procedures to prevent harm to the environment or communities or it may assist you in resolving the problem that led to the complaint through a dialogue with those implementing the project. Additionally, the PCM has the authority to recommend a project be suspended in the event that harm is imminent.

You can contact the PCM at: pcm@ebrd.com or you can submit a complaint online using an online form at: http://www.ebrd.com/eform/pcm/complaint_form?language=en

You can learn more about the PCM and how to file a complaint at: http://www.ebrd.com/work-with-us/project-finance/project-complaint-mechanism.html